Ionis Pharmaceuticals Inc
IONS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000874015
In the last 90 days, Ionis Pharmaceuticals Inc insiders filed 1 open-market purchase and 2 sales; 464 institutions reported holding it in 13F filings for Q3 2026, worth $7.66B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Market capClose on Nov 19, 2026
- $4.53B
- Insider buysLast 90 days, $148.2K in total
- 1
- Insider sellsLast 90 days, $61.4K in total
- 2
- 13F holdersQ3 2026, −45 vs. previous quarter
- 464
- 13F valueReported value at the end of Q3 2026
- $7.66B
- Superinvestors holdingAt the end of Q3 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $943.7M
- +33.8% year over year
- Net income, FY2025
- -$381.4M
- No comparable prior period
- Free cash flow, FY2025
- -$320.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $242.7M
- +54.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $381.4M (40.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 21.2M
- Shares sold short
- Change
- +512.8K
- +2.5% vs. previous
- Days to cover
- 8.41
- At average daily volume
Superinvestors holding IONS, Q3 2026
Go to the superinvestors tab1 superinvestor reports holding Ionis Pharmaceuticals Inc on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Ionis Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 13, 2026 (view filing)4:19 PM ET | Nov 10 | 3 days | Hayden Michael RDirector | PPurchase | +5.00K | $29.64 | +$148.2K | +22.7%27.0K after | |
| Oct 19, 2026 (view filing)9:40 PM ET | Oct 16 | 3 days | Devers Shannon L.EVP, Chief Human Resources Ofc | SSale | −1.36K | $43.54 | −$59.1K | −7.1%17.8K after | |
| Oct 19, 2026 (view filing)9:40 PM ET | Oct 16 | 3 days | Swayze EricEVP Research | SSale | −53 | $43.54 | −$2.31K | −12.0%390 after | |
| Jul 31, 2026 (view filing)4:42 PM ET | Jul 30-31 | 1 day | Hayden Michael RDirector | PPurchase | +20.0K | $52.94 | +$1.06M | +500.0%24.0K after | 2 lots |
| Jul 9, 2026 (view filing)7:26 PM ET | Jul 7 | 2 days | Bennett C FrankEVP, Chief Scientific Officer | SSale | −5.54K | $83.58 | −$462.7K | −6.9%75.0K after | 10b5-1 |
| Jul 9, 2026 (view filing)7:26 PM ET | Jul 7 | 2 days | Bennett C FrankEVP, Chief Scientific Officer | SSale | −15.0K | $85.46 | −$1.28M | −100.0%0 after | 10b5-1 |
| Jul 9, 2026 (view filing)6:07 PM ET | Jul 7 | 2 days | Diaz Allene M.Director | SSale | −10.1K | $85.42 | −$863.6K | −72.6%3.81K after | 10b5-1 |
| Jul 9, 2026 (view filing)6:07 PM ET | Jul 7 | 2 days | Kordasiewicz Holly B.EVP, Chief Development Officer | SSale | −362 | $84.30 | −$30.5K | −1.6%22.1K after | 10b5-1 |
| Jul 6, 2026 (view filing)6:49 PM ET | Jul 1 | 5 days | Klein Joseph IIIDirector | SSale | −11.5K | $79.04 | −$910.4K | −51.1%11.0K after | 2 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Baroldi JosephEVP, Chief Business Officer | SSale | −5.63K | $80.16 | −$451.7K | −54.7%4.67K after | 10b5-1 |
Top 10 13F holders, Q3 2026
See all 464 holdersThe largest institutional positions in Ionis Pharmaceuticals Inc at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 24,740,108 | $1.10B | 0.05% | +108,152+0.4% | Added |
| Capital World Investors | 21,787,273 | $972.8M | 0.12% | +118,047+0.5% | Added |
| BlackRock, Inc. | 13,192,834 | $589.1M | 0.01% | +2,488,174+23.2% | Added |
| Vanguard Portfolio Management LLC | 7,719,464 | $344.7M | 0.02% | −140,065−1.8% | Reduced |
| Vanguard Capital Management LLC | 7,218,530 | $322.3M | 0.01% | +7,033+0.1% | Added |
| Two Sigma Investments, LP | 6,727,410 | $300.4M | 0.22% | +475,068+7.6% | Added |
| State Street Corp | 5,710,900 | $255.0M | 0.01% | +1,376,052+31.7% | Added |
| Citadel Advisors LLC | 4,026,275 | $179.8M | 0.10% | +3,789,991+1,604.0% | Added |
| Wellington Management Group LLP | 3,430,545 | $153.2M | 0.03% | −4,220,870−55.2% | Reduced |
| Geode Capital Management, LLC | 3,277,569 | $146.4M | 0.01% | −306,455−8.6% | Reduced |
Holders of 5% or more of IONS
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Ionis Pharmaceuticals Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Capital World Investors | 13G/A | 12.80%21.2M shares | +1.70 ppfrom 11.10% | Feb 13, 20253 filings | May 14, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 5.70%9.07M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| Vanguard Capital Management LLC | 13G | 5.05%8.34M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
Politician trades
All politician trades in IONS2 members of Congress reported 3 trades in Ionis Pharmaceuticals Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Apr 17, 2023 | Daniel S. Goldman House · NY | Sell | $1K-$15K |
| Apr 27, 2020 | Donna E. Shalala House · FL | Sell | $1K-$15K |
| Apr 27, 2020 | Donna E. Shalala House · FL | Buy | $1K-$15K |

House · NY · Apr 17, 2023
Sell$1K-$15K

House · FL · Apr 27, 2020
Sell$1K-$15K

House · FL · Apr 27, 2020
Buy$1K-$15K